Smith & Nephew's Lobbying Activities in 2026: Focus on Medicare and Security

Smith & Nephew Inc. has reported $490,000 in lobbying expenses for the second quarter of 2026, as detailed in a recent Lobbying Disclosure Act filing. The company's lobbying efforts concentrated on several key issues, including the Medicare physician fee schedule and outpatient rule. They also focused on legislative measures such as the Skin Substitute Access and Payment Act of 2025 (H.R. 5768/S. 2561), as well as Medicare local coverage determinations for skin substitutes.

Beyond healthcare policies, Smith & Nephew's lobbying activities extended to domestic security concerns, specifically around personal protective equipment (PPE) and essential medicines for Medicare hospitals. They also addressed Medicare complexity adjustments in outpatient and ambulatory surgical center settings. Moreover, the company engaged in discussion on Section 301 and Section 232 investigations related to forced labor and medical devices, along with issues concerning the USMCA trade agreement. Their aim was to inform key government officials about product applications for military use and to solicit support for appropriations requests.

Quiver Quantitative provides additional insights into corporate lobbying and investor trends. During the last quarter, 154 institutional investors added shares of Smith & Nephew to their portfolios, while 86 decreased their stakes. Quiver Quantitative’s platform, particularly their API 13F endpoint, delivers valuable data about hedge fund stock portfolios and 13F filings. However, users should consult Quiver Quantitative's disclaimers for guidance, as this information does not constitute financial advice.